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INTRODUCTION 
Hodgkin lymphoma constitutes around 1% of all cancers worldwide and about 
12% of lymphomas1. This neoplasm was first recognized a century ago by 
Thomas Hodgkin and Samuel Wills. It is characterized by heterogeneous 
cellularity comprising of minority of specific neoplastic cells, the Reed 
Sternberg cells. Though extensive and intensive research has happened in the 
field of Hodgkin lymphoma for years, there are many unanswered questions 
like the exacT-cell lineage of the neoplastic cells, clonality, the reason for the 
sparcity of the neoplastic RS cells, the cause for its multinuclearity and whether 
the histological subtypes are different disease entities or just variants of the 
same disease2, 3. 
 Epidemiological, molecular and immunologic evidences link Hodgkin 
lymphoma to EBV infection4. Histochemical assays are widely used for 
localizing EBV nucleic acid or protein in the malignant Reed Sternberg 
/Hodgkin cell. EBV virus expresses latent membrane protein which can be 
detected immunohistochemically or by EBER, which is the viral RNA detected 
by in situ hybridization5. 
Our study is aimed at identifying the EBV expression in the neoplastic RS cells 
and the usage of Ki-67 as a prognostic marker6 in Hodgkin lymphomas. 
AIMS AND OBJECTIVES 
1. To analyze the expression pattern of Epstein - Barr Virus (EBV) Latent 
Membrane Protein 1(LMP1) and Ki-67 in various histologic subtypes of 
Hodgkin lymphoma. 
2. To compare the expression of Epstein - Barr Virus Latent Membrane 
protein 1(LMP1)  with CD15 and CD30 expression of Reed- Sternberg 
cells in Hodgkin lymphoma 
3. To correlate the Ki-67 expression with the clinical stage and other 
prognostic parameters. 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
Lymph node is a small bean shaped organ situated in the course of lymphatic 
vessels such that the lymph draining back to the blood stream is passed through 
one or more lymph node7. 
The main function of lymph node is to deal with any foreign body entering the 
body. This can be done in three ways 
 Ignore the foreign substance 
 Destroy it 
 Clear it 
Depending upon the type of foreign body (antigen) our immune system will 
decide which course of action to take. As our body encounters many antigens 
continuously lymph nodes are distributed throughout the body. Lymph nodes 
are seen in skin, in areas where lymphatics drain like axillary, cervical and 
inguinal region. MALT is mucosa associated lymphoid tissue which is present 
in gastrointestinal tract. The lymph which is collected throughout the body gets 
converged into a single channel called thoracic duct. The thoracic duct in turn 
returns the lymph which it has collected into the blood stream. Brain is the only 
organ in the body which has no lymphatics. Hence CSF takes this role and fluid 
from brain gets drained into it8.  
The outer part of lymph node is highly cellular and is called the cortex while 
the central part is the less cellular medulla. Lymph node is surrounded by 
collagenous capsule from which trabeculae extend for variable distance7. 
The four main compartments of a lymph node are the 
 Follicles 
 Medullary cord 
 Paracortical area 
 Sinuses 
Lymphocyte collections form follicles which are normally round structure with 
pale center and dark rim. The center has a mottled appearance. The follicles are 
more concentrated in the cortical area. The follicles are of two types primary 
and secondary. Primary follicles comprise of small dark staining lymphoid 
cells. Around the follicles is the zone called mantle zone. It has the same 
characteristics as primary follicle. The outer portion of mantle zone is 
somewhat less densely packed compared to inner layer. This outer rim is called 
the marginal zone8.  
Between follicles extending to the deeper parenchyma is the ill defined area 
called Para cortex or Para cortical area. It is characterized by pronounced 
blood vessels and epithelioid or high endothelial venules. The central 
medullary region is dark and is separated by lighter staining areas in a reticular 
pattern. The darker stained areas represent the medullary cords. The dark area 
is constituted by plasma cells and masT-cells. The lighter area is made up of 
sinus histiocytes which have a paler cytoplasm and hence the area appears 
lighter8.     
The framework of lymph node is made up of reticulin fibers. Beneath the 
capsule is the space called sub capsular sinus. Though the sinuses run 
throughout the parenchyma they are prominent in the medullary zone and 
directly beneath the capsule. 
DifferenT-cells are seen in particular areas of lymph node. The germinal 
centers contain B-cells, T-cells, tingible body macrophages and dentritic 
reticulum cells. Mantle zone has memory B-cells and marginal zone has 
monocytoid cells. Paracortical area comprises mainly T-cells whereas 
medullary area is rich in plasmablast and plasma cells. 
Blood supply 
Blood vessels enter lymph node at the region of hilum. Usually the arterioles 
and venous system run together. 
Embryology 
Differentiation into cortex and medulla takes place by second trimester.  
LYMPH NODE ARCHITECTURE 
 
 
Source:  Euro cytology, Normal lymph node histology 
Lymphomas 
Lymphomas and leukemias are malignancies which arise from the lympho 
reticular system. Leukemias usually involve the bone marrow and lymphomas 
involve discrete solid tissue masses. There are two types of lymphomas namely 
Hodgkin lymphoma and non - Hodgkin lymphoma1.  
History  
Malignant lymphoma was first used by Billroth to define the lesions involving 
lymphoid tissue. Lymphomas were divided into Hodgkin lymphoma and non - 
Hodgkin lymphoma because both had variation in histological features as well 
as in the pattern of behavior2.  
It was Dr. Thomas Hodgkin who first described this condition and hence this 
lymphoma is named after him. The characteristic feature in Hodgkin 
lymphoma is the Reed Sternberg cell, also called the RS cell. It is a type of 
multinucleated gianT-cell with characteristic owl’s eye appearance. 
These cells were first described by two doctors namely Dr. Sternberg in the 
year 1898 followed by Dr. Reed in the year 1902. In mid 1940s, the manual of 
international list of causes of death classified this lymphoma as an infectious 
disease. 
 
 
 
Risk factors associated with Hodgkin lymphoma are 
 Occupation 
 Genetic predisposition 
 Clusters 
 Others 
 Infections 
- Epstein - Barr Virus 
EBV was initially thought to cause Infectious mononucleosis and Burkitt’s 
lymphoma. But later, studies revealed that Epstein - Barr virus is an oncogenic 
virus which can be associated with various malignancies like Hodgkin 
lymphoma, non - Hodgkin lymphoma and nasopharyngeal carcinoma. EBV’s 
latent membrane protein was detected in the Reed Sternberg cell by 
immunohistochemistry. Various factors like age, sex, ethnicity and histological 
subtype contribute to the prevalence of EBV in Hodgkin lymphoma. 
1944:  Jackson and Parker classified lymphomas as 
 Paragranuloma 
 Granuloma 
 Sarcoma 
1966: there was the Rye conference where Hodgkin lymphoma were classified 
as 
 Lymphocyte depleted 
 Lymphocyte predominant 
 Nodular sclerosis 
 Mixed cellularity 
        REAL classification  
 
Classical Hodgkin lymphoma           Nodular lymphocyte predominant 
Lymphocyte rich 
Lymphocyte depleted 
Mixed cellularity 
Nodular sclerosis 
WHO classification (2008) 
 Classical Hodgkin lymphoma 
Lymphocyte rich 
Nodular sclerosis 
Lymphocyte depleted 
Mixed cellularity 
        Unclassifiable 
 Nodular lymphocyte predominant Hodgkin lymphoma 
HODGKIN LYMPHOMA 
There are two types of lymphomas namely Hodgkin lymphoma and non-
Hodgkin lymphoma. There are many differences that exist between Hodgkin 
lymphoma and Non-Hodgkin lymphoma such as non-Hodgkin lymphoma 
involves predominantly extra nodal site while Hodgkin lymphoma involves 
single node or group of contiguous nodes.  Spread of HL is through contiguous 
lymph node whereas unpredictable spread is one of the characteristics of NHL9. 
HL predominantly involves axial group of lymph nodes while NHL involves 
the peripheral nodes.  Mesenteric nodes and Waldeyer ring involvement are 
rare in HL while its involvement is commonly seen in NHL.  
There are two forms of HL namely: Classical form and Lymphocyte 
predominant form. The classical form includes nodular sclerosis, mixed 
cellularity, lymphocyte rich and lymphocyte depleted. They are grouped under 
one category because the immunophenotype and morphology are similar. B-
cell immunophenotype is seen in case of lymphocyte predominant type and 
hence placed as a separate entity. REAL classification used the term classical 
HL to include nodular sclerosis, mixed cellularity, lymphocyte rich and 
lymphocyte depleted. 
HL is one of the malignancies which are still difficult to understand.  There are 
many questions regarding HL despite the extensive research involved.  There is 
no definitive answer regarding the cell lineage, clonality and a clear 
understanding about the RS cell and Hodgkin like cell.  The exact reason for 
the multi nuclearity of the RS cell is also not known and is postulated that it 
could be either because of cell fusion or the endomitosis which happens in 
these cells2.   
HL is a peculiar disease in the sense, the true neoplastic cells i.e.,  RS cells 
contribute to a very small quantity of the tumor bulk and it is the non-dysplastic 
cells like the various inflammatory cells like lymphocytes, neutrophils, 
eosinophils, plasma cells and histiocytes which predominates. There is also a 
question regarding the sub-types of HL as to whether they represent different 
diseases or they are just variants of a single disease.  Gene rearrangement 
studies to know the antigen receptors show so much variation and there is no 
correlation between these studies and the amount of HRS cells which are found 
in the tissue examined2.  
 The reason for the variation in the incidences of EBV infection in HL and 
among different sub-types is also not exactly known. There is no proper 
correlation between the karyotypes, mutation in p53 gene and DNA content. 
A proper understanding and knowledge regarding HRS cells seen in HL is not 
available still because of the difficulty in isolating HRS cells in the tissue 
biopsies. HRS cells are very fragile and there are abundant background 
inflammatory cells which are the obstacles in studying the HRS cells. This 
problem can be solved by purifying the HRS cells to remove the other 
inflammatory cells and to cultivate them in vitro by providing enrichment 
medium.  
As a result, many cell lines have been developed and antibodies produced 
against the RS associated antigens like CD30, CD70. These cell lines are also 
useful for various genotypic and phenotypic studies. It is found that the HRS 
cells have a lymphocytic origin because of the genotypic and phenotypic 
expression of B or T-cells by these cell lines. But it cannot be concluded that 
they have this origin because it is still impossible to get a pure HRS cell from a 
tissue due to dense mixture of other inflammatory cells2. 
Earliest studies regarding HL were done by Mac Mohan, who found that HL 
had a bimodal age distribution with the first peak occurring between 15 and 34 
years and the second peak occurring after 50 years.  He also classified the ages 
into three groups as:  0 -14, 15-34 and above 50 years. According to him, HL 
was more common in boys. Infection was found to be the main cause of HL in 
young people and there was increased occurrence in high socio-economic class.  
Males were more commonly affected in the elderly population10.  
The incidence of HL varies and is dependent on many factors like geographic 
location, age of affected person, sex, social class, immune status, infectious 
etiologies and genetic susceptibility. There is also variation in the incidences of 
HL between developing and developed countries11.  
In industrialized developed nations, the first peak of HL is in the third decade 
while the second rise is after the fifth decade. Bimodal age distribution is more 
common in developed nations and increase in age is directly proportional to the 
increase in the incidences of HL12. 
This is in sharp contrast in the developing countries where the reverse happens. 
The incidence of HL is more common during the childhood period and as the 
age increases, there is a decline in the incidence of HL12.  
Whites are more commonly affected by HL than those in Asian countries like 
China and India13.  
NS is the most common type seen in the younger age group while in the older 
age group, MC type is the most common12. 
According to the WHO, HL has a bimodal age distribution with 49 percent 
cases occurring during the first peak and 47 percent of cases during the second 
peak.  The Male: Female ratio was 1.3: 1. Mixed cellularity constituted the 
major bulk (51 percent of HL cases) followed by nodular sclerosis 36 percent, 
lymphocyte depleted and lymphocyte predominant types constituted 5 percent 
each11.  
In western countries, 50 percent of HL cases were positive for EBV virus.  In 
places like Asia and Africa, the percent of infection with EBV is even higher 
with around 90 percent of children with HL being infected with EBV14, 15.   
In the young adult life, there exist an inverse relationship between the number 
of younger siblings and the occurrence of EBV positive HL. This could be 
explained by the late primary infection of EBV16. 
Three epidemiological patterns were identified by Correa and O’Connor in HL 
namely types I, II and III. Type I pattern was seen in the developing countries 
while type III occurred in developed counties. Type II was intermediate 
between type I and type II and was seen in developed countries which had a 
more rural area. Type I pattern is characterized by increasing incidence of HL 
in male children and second peak in older individuals.  Mixed cellularity and 
lymphocyte subtypes belong to this pattern. Type III pattern has a low 
incidence in children and an increased incidence in young people.  Nodular 
sclerosis subtype follows this pattern17. 
A strong genetic association and inheritance is found in younger age group HL 
where there is an increased interleukin 6 level and a reduced interleukin 12 
response18.   
The incidence of HL in younger people could be explained by a model called 
“Hygiene Hypothesis” which states that a complex interaction of various 
environmental factors and genetic factors are needed for the occurrence of 
HL19.   
Some studies suggest the polyclonality of HL while other studies suggest 
monoclonality. Some subtypes of HL also exhibit a mixed clonality including 
both monoclonal and polyclonal pattern.  HL initially starts as a polyclonal 
disease but progresses to become a monoclonal disease20.   
The cellularity of the tumor is composed of large neoplastic cells called the 
Reed-Sternberg (RS) cells admixed with mixed cell population of lymphocytes, 
macrophages, eosinophils, neutrophils and plasma cells. Their presence is due 
to the release of factors from the neoplastic RS cells. These include cytokines 
like IL-5, monocyte colony stimulating factor, IL-10 and chemokine like 
Eotaxin and immunomodulatory factor like Galactin-1. There are many factors 
produced by the reactive cells which are responsible for the tumor cells 
survival9.   
PATHOGENESIS 
The pathogenesis of HL involving RS cells have been studied for a long time 
and found that they originate from the germinal centre B-cells. Both somatic 
hyper mutation and DJ recombination takes place in the Ig gene which is 
present in the RS cells.  But still, Ig gene which is one of the most important 
and significant gene of B-cells is not expressed by many RS cells.   
NF -B is an important transcription factor and activation of this factor plays a 
key role in the survival of lymphocyte as well as its proliferation by the 
activation of certain genes. Up regulation of NF-B happens by latent 
membrane protein-1 which is a protein present in EBV. NF-B has two 
important negative regulators namely I B and A 20.  A mutation in these 
negative regulators would lead to the activation of NF-B. Chromosome 2p 
contains the RET proto-oncogene. NF-B activity is increased by the RET 
proto-oncogene. RS cells contain CD30 and CD40 receptors. These receptors 
are activated by the ligands which are expressed in the eosinophils and T-cells9.   
REED - STERNBERG CELLS  
These cells are large with a diameter of around 45 micrometers and can have a 
single nucleus, multiple nuclei or a single nucleus with multiple lobes. The 
characteristic finding in the RS cells is the presence of large eosinophilic 
nucleolus which looks like an inclusion and is characteristically called as owl’s 
eye appearance. The size of the nucleolus ranges between 5 to 7 micrometer 
diameter and is almost equal to the size of a small lymphocyte.  
There are many other cells which have a similar morphology and are called as 
RS like cells or Hodgkin cells. They include lacunar cells, popcorn cells and 
lymphohistiocytic variant. Lacunar cells have an artifactual disruption of 
cytoplasm during processing and have pale cytoplasm. It has the appearance of 
an empty hole with a nucleus sitting in it. Lacunar cells are most often found in 
nodular sclerosis type of Hodgkin lymphoma. Lymphocyte predominant type 
has the characteristic popcorn cell or lymphohistiocytic cell. They have 
moderate amount of cytoplasm with polypoid nuclei. Mononuclear variant has 
a single nucleus. Mummification is the form in which the RS cells become 
pyknotic. RS like cells are also seen in many diseases like infectious 
mononucleosis and non - Hodgkin lymphoma.   
The RS cells have diverse clonal chromosomal aberration and they are 
aneuploids.  Lymphocytes, plasma cells and macrophages accumulation is due 
to the factors released from the RS cells including various chemokines and 
cytokines. Initially it was thought that the RS cells had their origin from the 
dendritic cells and macrophages, but now it is clear that the RS cells have their 
origin from T or B-cell. The clonality of RS cells and hence the cell of origin 
has been studied by PCR technique using individual RS cells. 
The non-neoplastic inflammatory cell background plus the RS cells are 
important clues to the diagnosis of Hodgkin lymphoma. The sub typing of HL 
is based on the background reactive population, the various morphological 
forms of RS cells and fibrosis9.  
NODULAR SCLEROSIS CLASSICAL HODGKIN LYMPHOMA: 
It is the most common sub-type. Around 65 - 70 percent of HL belongs to this 
type. Most common site affected by nodular sclerosis is the mediastinum. The 
morphology consists of nodules separated by dense bands of collagen. The 
predominanT-cell is the lacunar cells in a background of mixed reactive cell 
population. The classical RS cells are usually not found. Reticulin stain shows 
regular parallel arrangement of the collagen fibers which are birefringent using 
the polarized light. The immunohistochemical markers positive in nodular 
sclerosis subtype are CD15, CD30 and PAX5. It is usually associated with 
excellent prognosis2, 9.   
MIXED CELLULARITY CLASSICAL HODGKIN LYMPHOMA: 
20 to 25 percent of HL is comprised of this type. There is diffuse infiltration of 
lymph node by mixed inflammatory cells infiltrate composed of lymphocytes, 
plasma cells, eosinophils and histiocytes. RS cells are seen scattered among 
these cells. Mixed cellularity subtype has more of RS cells. It is more 
commonly associated with male gender and older age. The incidence of this 
type is biphasic with the first peak occurring at young age and second peak at 
greater than 55 years. The B symptoms seen in lymphoma like night sweats, 
fever and weight loss are more evident in this type.  Mixed cellularity type is 
also found to have a good prognosis1. 
LYMPHOCYTE- RICH CLASSICAL HODGKIN LYMPHOMA: 
As the name suggests, this lymphoma is composed predominantly of 
lymphocytes which are scattered diffusely leaving the lymph node with effaced 
architecture. Mononuclear form and RS cells are seen in this type. The 
prognosis of lymphocytes rich subtype is also good9.   
LYMPHOCYTE DEPLETED CLASSICAL HODGKIN LYMPHOMA: 
It constitutes less than 5 percent of Hodgkin lymphoma. Older population and 
HIV infected individuals are more commonly affected by this type. 
Microscopically there is a sparcity of lymphocytes but the classical RS cells as 
well as its variance are seen in abundance. The differential diagnosis of 
lymphocyte depleted type is large cell non - Hodgkin lymphoma. Hence an 
immune phenotyping has to be done to confirm this subtype2.   
The RS cells which are seen in nodular sclerosis, mixed cellularity, lymphocyte 
depleted Subtypes have a similar antigenic profile while the popcorn cells, also 
called the lymphohistiocytic cells have a different antigenic profile. Hence it is 
important to differentiate this subtype from lymphocyte predominant Hodgkin 
lymphoma. There is a variation in the course of the disease and the clinical 
outcome as well. The classical types are usually fatal if left untreated whereas 
lymphocyte predominant Hodgkin lymphoma has an indolent course and there 
is no progression of the disease even without treatment9. 
NODULAR LYMPHOCYTE PREDOMINANT HODGKIN 
LYMPHOMA: 
Less than 5 percent of Hodgkin lymphoma is comprised of this type. There is 
effacement of lymph node architecture by infiltration of lymphocytes. Vague 
nodular formation is usually seen. There are only scant RS cells but its variant, 
the popcorn cell or lymphohistiocytic variant with multilobed nuclei are 
commonly seen. The lymphocytes and popcorn cells are admixed with 
macrophages and a very few eosinophils and plasma cells9. 
The characteristic immunophenotype of lymphocyte predominant type is the 
positivity for CD20 and BCL 6 and negativity for CD15 and CD30. CD20, the 
marker for germinal B-cells is positive and hence around 5 percent of this 
subtype can transform into B-cell lymphoma. This subtype is common in 
younger males. Recurrence is common in this subtype but has an excellent 
prognosis2.   
Lymphocyte predominant HL was most often confused with T-cell rich B-cell 
lymphoma and with classical Hodgkin lymphoma - lymphocyte rich subtype. 
There are two forms of LPHL namely nodular LPHL which are well defined 
lesion and diffuse LPHL.  Nodular LPHL is characterized by the presence of 
many large follicular dendritic cells which form a meshwork with B-cells, T-
cells and RS cells. The B-cells and follicular dentritic cells are not seen in case 
of diffused LPHL and the T-cells are seen predominantly in the background2.  
Though the lymphocyte rich subtype of HL also has dense amount of 
lymphocytes like LPHL, the antigenic profile is different in both.  
It is important to differentiate T-cells rich B-cell lymphoma from DLPHD 
because the former has a very aggressive course, involves the bone marrow 
early and needs immediate treatment in contrast to the diffuse lymphocyte 
predominant Hodgkin disease which has an indolent course. But it has been 
very difficult to distinguish DLPHD from TCR-BCL by morphology and 
immunophenotype. 
Some authors believe that DLPHD and TCR –BCL are one and the same and 
that TCR-BCL could be a variant of DLPHD instead of a separate entity.  But it 
is found that TCR-BCL is more heterogeneous disorders in the sense, few 
forms are similar to DLPHD and others have a diffuse large B-cell lymphoma 
picture2.  
The other areas of overlap are between classical Hodgkin lymphoma and 
anaplastic large cell lymphoma as they share similar features. In cases where 
there is an overlap, it would be better to call it as anaplastic large cell 
lymphoma - Hodgkin disease like lymphoma as this entity is found to be more 
aggressive. The treatment modality also varies and the regimen used for 
treating high grade non - Hodgkin lymphoma should be given instead of that 
used for classical Hodgkin disease1. 
LPHD expresses different antigen and hence regarded as a separate entity. The 
various antigens expressed on the RS cells in LPHD are J chain, CD20 and 
CD79a among others. The RS cells in classical Hodgkin lymphoma express 
CD15 and CD30 but do not express markers for interdigitating cells and 
macrophages. In classical HL, there is heterogeneity in the B and T-cells 
antigen expression. Hence there is an aberrant gene expression seen in HL2. 
 
ALGORITHM FOR THE DIAGNOSIS AND SUBTYPING OF 
HODGKIN LYMPHOMA 
EFFACED LYMPH NODE ARCHITECTURE 
 
PRESENCE OF RS CELLS/VARIANTS (+) 
 
LOOK FOR BACKGROUND POPULATION (+) 
  
 
           
           
          
   MOSTLY HODGKIN  
         LYMPHOMA 
MIXED INFLAMMATORY 
POPULATION + RS CELLS -     
MIXED CELLULARITY 
INCREASED LYMPHOCYTE S + 
MONONUCLEAR FORM 
- LYMPHOCYTE RICH 
FEW LYMPHOCYTES + RS 
CELLS 
-   LYMPHOCYTE DEPLETED 
INCREASED LYMPHOCYTES + 
POPCORN CELLS -  
LYMPHOCYTE  
PREDOMINANT 
 
NODULES + LACUNAR CELLS 
  -  NODULAR SCLEROSIS 
Though immunohistochemistry and molecular advancements have made the 
diagnosis of lymphomas easier, clinical history and physical examination are 
also important in the diagnosis of HL. These include: 
 Sex 
 Age 
 Duration of illness 
 H/O B symptoms 
 H/O any treatment 
Examination 
 Site 
 Lymphadenopathy 
 Hepatosplenomegaly 
 Skin lesion 
 Proven infection with HIV, EBV, HCV 
All these parameters are essential to aid in the diagnosis of lymphoma and 
classify them. The patients usually present with lymph node involvement or 
systemic symptoms. The lymph node is enlarged, non tender and commonly 
involves the neck nodes.  It is usually picked up by the physical examination 
and it is not noticed by the patients. Sometimes they can present as an anterior 
mediastinal mass which is picked up by a chest X-Ray. The mass is 
asymptomatic though large. Intra thoracic involvement and parasternal mass 
can also be seen. Systemic symptoms include unexplained weight loss, fever, 
night sweat, fatigue and pruritis. Evening rise of fever is more common and the 
night sweat may or may not be associated with fever. Waxing and waning type 
of fever called Pel - Ebstein fever is seen in HL. It is characterized by a peak 
rise of temperature which lasts for one to two weeks followed by a fall and rise 
again2.   
Pruritis is another non specific symptom which if not recognized due to HL can 
lead on to severe excoriation, secondary changes, generalized involvement and 
hyperpigmentation. 
Systemic symptoms predominate in the occult form of HL. Though there is 
painless lymphadenopathy in most of the cases, some patients might have a 
tender lymph node as well. Rare clinical presentations include symptoms due to 
anemia, thrombocytopenia, neutropenia and immunosupression. Abdominal 
swelling might be seen. Ascites, jaundice, neurologic deficit and intracranial 
presentation are very rare.  
 
 
 
 
COTSWOLDS MODIFIED ANN ARBOR STAGING FOR HODGKIN 
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The common makers used in the work up for HL are CD15, CD30, CD40, CD 
45, CD20, EMA and CD3. 
CD30 
CD30 belongs to the family of TNFR or nerve growth factor receptor. B, T-
cells and NK cells are found to express CD30 ensuing a viral transformation or 
activation of mitogen.  But many studies have found that CD30 expression is 
found in many other cells like macrophages, faT-cells and activated monocytes. 
This raised the question as to whether CD30 represent a specific marker for 
lymphoid activation. 
Some studies have found that the expression of CD30 on all other cells except 
lymphoid cells were an artifact. In paraffin sections, CD30 antibody was 
expressed by the plasma cells, endothelial cells, epithelial cells and 
macrophages in addition to the HRS cells. But it was found that this staining 
was artifactual due to the paraffin sections which were overdigested. Hence the 
newer antigen retrieval methods use citrate buffers to overcome this problem1, 
2.   
CD40 
It belongs to the TNFR family. It is expressed consistently on the B-cells. It 
plays a role in the survival of the B-cells in the germinal centers. CD40 is not 
only constantly expressed by the HRS cells but also by other cells like 
macrophages and thymic epithelium2. 
CD15 
It is a myeloid marker. It is usually expressed in case of classical Hodgkin 
lymphoma disease in the RS cells while it is usually not seen in case of 
lymphocyte predominant Hodgkin lymphoma RS cells which are the 
lymphohistiocytic cells. Lineage cannot be assessed by CD15 as it is expressed 
by both B-cells and T-cells. It is also expressed by the macrophages, epithelial 
cells, RS like cells seen in cases of Infectious mononucleosis and also in some 
cases of non - Hodgkin lymphoma1, 2.  
CD20 
It is a B-cell marker. LPHL has the L&H type or popcorn cells which are 
variants of RS cells. They usually express CD20 and J chain. LPHL are also 
positive for CD79a, which is a specific B-cell marker. The HRS cells of 
classical HL can show any of the following 4 patterns in relation to B-cell and 
T-cell marker expression as follows1 
Pattern B antigen T antigen 
1 + - 
2 - + 
3 + + 
4 - - 
 
The HRS cells could express either B antigen or T antigen, both or none. 
The immunophenotyping done on the HRS cells of classical Hodgkin 
lymphoma and LPHD varies considerably. The classical HL has both B and T-
cell type similar to NHL whereas LPHD has only B-cell type. 
Clonality of the HRS cells could not be defined by immunolabelling. 
Immunoglobulins are negative in HRS cells in frozen section. But the HRS 
cells are positive for kappa and lambda light chain in paraffin section. This 
paradox could be due to the immunoglobulin uptake from the serum which can 
happen during formalin fixation. There is less intense staining of kappa and 
lambda chain in case of LPHD2. 
    CD15 AND CD30 
 
(+)            ( - ) 
CLASSICAL HODGKIN LYMPHOMA    
Do CD20, CD45 
 
        (+) 
LYMPHOCYTE PREDOMINANT HODGKIN 
LYMPHOMA 
 
HASENCLEVER INDEX 
It is also called as the International prognostic score. It is a multivariate 
analysis which can be used in Hodgkin lymphoma to predict the outcome of the 
disease henceforth preventing either an undertreatment or overtreatment. It 
predicts the five year freedom from the progression of Hodgkin lymphoma. 
The predictive rate would be reduced by around 8% for every additional 
adverse prognostic factor. This index was designed in 1980s for the Hodgkin 
lymphoma patients who were treated with various chemotherapeutic regimens 
like MOPP and ABVD. Various prognostic factors were taken into 
consideration and the prognostic score was the number of adverse prognostic 
factors present. The factors include  
 Serum albumin < 40g/L 
 Hemoglobin < 10.5g/dL 
 Male sex 
 Ann Arbor stage IV 
 Age > 45 yrs 
 Total WBC > 15 x109 /L 
 Lymphocyte count > 0.6x109/L 
Hasenclever index can also be used to determine the prognosis of the patients 
who have relapsed HL or patients who are refractory to treatment and those 
patients planned for autologous stem cell transplantation. 
EBV 
EBV comes under the family of Herpeviridae and gamma Herpeviridae 
subfamily. It belongs to the lymphocryptovirus genus. It is an enveloped virus 
with an ecosadelta-hedral nucleocapsid. Tegument is a protein which is 
amorphous and is present inbetween the capsid and envelope. It is a DNA virus 
and has a linear double stranded DNA. This virus can be inactivated by UV 
light, disinfectant and gamma radiation. Low temperature maintains the 
stability of this virus and it prefers a temperature of -60 degree Celsius or 
below. Heat inactivates the virus and the temperature range of 50 to 60 degree 
Celsius for a period of 30 minutes is needed for the viral inactivation. The 
survival time of EBV at various circumstances is as follows: 
 Room temperature - few days 
 Refrigeration - 2 to 3 days 
 -70 degree Celsius - Many years  
The most common source of infection with EBV is secretions contaminated 
with this virus like saliva, breast milk and semen. Respiratory tract and mucous 
membrane are the common routes through which human exposure happens. It 
is not transmitted through parenteral route22.   
The immunocompromised people and patients who have undergone organ 
transplantation, either bone marrow or solid organs are at greater risk of 
acquiring EBV infection. 
Infected humans are the reservoir for EBV. Once infected, EBV can remain in 
the B lymphocyte throughout the life as latent virus. This latent virus can then 
be reactivated to cause various diseases. Hence once infected, the person 
becomes a lifelong carrier. The incubation period for the virus varies in adult 
and children. Adults have a longer incubation period of around 4- 7 weeks 
whereas it is only 1- 2 weeks in children. Usually the primary disease manifests 
as fever, pharyngitis, head ache and lymphadenopathy.  
It has been found that little quantity of EBV DNA is present in the peripheral 
blood of people who are healthy as well as those with cancer23. 
There is presence of EBV DNA in the peripheral blood in case of 
nasopharyngeal carcinoma and post transplant lymphoproliferative disease and 
NK/Tcell lymphoma. This led to the search of EBV in Hodgkin lymphoma24-27. 
The associated B symptoms of HL like night sweats, fever, weight loss, 
elevated ESR may point towards an underlying infectious agent for Hodgkin 
lymphoma28. 
The following conditions are needed for the EBV infection to have a role in 
oncogenesis : 
* The cells should continue to have the viral genome 
* EBV should not destroy the cell 
* EBV infected cell should not be destroyed by the immune system 
* There should be activation of pathways of cellular growth control29. 
For the persistence of the virus in the cells, it is necessary for the EBV to 
produce a latent infection. This is achieved by infecting the B lymphocytes 
with EBV virus. There is an integration of EBV genome with B lymphocytes 
either by producing multiple copies of circular episomes or by the integration 
of the host genome and viral DNA. After integration, replication of the B 
lymphocytes happens and the virus is also transmitted to the cell progeny thus 
maintaining its existence. At this stage, they are not oncogenic but either 
continued, uncontrolled proliferation or oncogenic mutation would make these 
cells neoplastic. The body tries to tackle these crises by mounting a cytotoxic 
T-cell response which cuts down the B-cell proliferation. But the EBV 
manages to enter the memory B-cell.  
The EBV infection in the memory B-cells normally express EBNA1 and does 
not express the pathogenic EBV latent genes. The EBV infected cells which 
express EBNA are usually skipped by the immune surveillance because of the 
reduced cytotoxic response to EBNA1. This leads to the continued persistence 
of EBV in the cells and act as the viral reservoir. Viral replication occurs by the 
lytic cycle leading to the release of the virions. The infected cells are destroyed 
because of the host protein synthesis suppression by this virus. The chain of 
events continues with more and more cells being infected with virions29. 
There is increased proliferation of EBV infected cells in the peripheral blood, 
lymph node and oropharynx when there is an immune suppression. The cell 
proliferation happens by the activation of various intracellular signals and this 
plays a key role in the transformation of EBV into oncogenes. Hodgkin 
lymphoma, Burkitt’s lymphoma, nasopharyngeal carcinoma and other 
malignancies develop after a few years of infection with EBV by the activation 
of various cellular transduction pathways by viral genes29. 
EBV and Lymphoma 
T-cell, NK cell and B-cells are infected by EBV leading on to various types of 
malignancies. Hydroa vacciniforme - like lymphoma is a recent entity which is 
also found to be associated with EBV. But the exact role of this virus in each of 
the malignancies is not clear so far30.  
 EBV virus has glycoproteins gp 350/220, gH /gL /gp 42. B-cells have CD21 
and HLA class II. Gp 350/220 gets attached to the CD21 and gH /gL/g p42 gets 
attached to the HLA class II. The primary EBV receptor is CD21 and gp 
350/220 is the viral envelope glycoprotein. gH /gL /gp are the viral 
glycoprotein complex and HLA class II is the co-receptor.   
There are two forms of infection seen in EBV namely primary infection and 
latent infection. During primary infection, EBV infects T-cell, epithelial cell 
and NK cell but most commonly Waldeyer's ring epithelial cells are affected by 
EBV31, 32.EBV infected cells come into contact with natural killer cells, thereby 
directly acquiring EBV infection. Monocytes also get infected by EBV virus by 
mechanisms not clear33.   
There are four types of latency namely 0, I, II and III. 
In latency 0, there is only EBER expression seen. Latency 0 is seen in memory 
B-cells infected with EBV. 
EBNA1, EBER and BART expressions are seen in case of type I latency. 
Burkitt’s lymphoma exhibits type I latency. 
Type II latency is characterized by the expression of EBNA1, BART, EBER, 
LMP1 and LMP2. Type II latency is seen in Hodgkin lymphoma sub groups 
namely mixed cellularity and nodular sclerosis.  
All EBV encoded genes are expressed in type III latency namely LMP 1 and 2, 
EBNA 1, 2, 3, EBER and BART. Post-transplant lymphoproliferative disorders 
exhibit type III latency30.  This classification is not rigid and EBV associated 
diseases can also exhibit a mixed heterogeneous pattern. This variation in gene 
expression could be seen even within the same tissue34, 35. 
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EBV virus is associated with mixed celluarity, lymphocyte depleted  and 
nodular sclerosis types of Hodgkin lymphoma, Burkitt’s lymphoma (both 
endemic and sporadic ) HIV associated lymphoma, angioimmunoblastic T-cell 
lymphoma, Hydroa-vacciniforme like lymphoma, post-transplant lympho 
proliferative disorders, lymphomatoid granulomatosis, plasmablastic 
lymphoma, extra nodal NK/T-cell lymphoma and diffuse large B-cell 
lymphoma of elderly36. 
EBV is also associated with newer entities which are still not included in the 
WHO classification like EBV associated haemophagocytic lymphohistiocytosis 
and chronic active EBV disease. 
EBV AND HODGKIN LYMPHOMA 
In early 1950s, a few studies found a relationship between infectious 
mononucleosis and Hodgkin lymphoma. EBV was the pathogen causing 
infectious mononucleosis and the RS cells were found to contain the DNA and 
the RNA of EBV. But it was found that, not all the HL cases were infected with 
EBV and there was a wide variation pertaining to various factors like age, the 
morphological and histological type of Hodgkin lymphoma and the geographic 
location.    
The relationship of HL between primary symptomatic cases verses primary 
infection per se is unclear. EBV associated HL are usually related with an 
inflammatory response. Hence if an EBV infected patient is symptomatic, then 
there are more chances of getting HL than the patients with asymptomatic EBV 
infection37.   
Regulatory T-cells also called Treg cells play an important role in controlling a 
foreign antigen entering the body and also have a role in autoimmune 
disorders.  HL cases are usually associated with an increase in the level of Treg 
cells.  Now it is found that Treg cells are elevated both in EBV positive and 
EBV negative Hodgkin lymphoma. 
Compared to inguinal lymph node, the cervical lymph nodes are often involved 
in EBV associated HL. This holds true in case of infectious mononucleosis as 
well37.   
40 percent of patients who have Hodgkin disease are found to have RS cells 
which are positive for EBV. Age, HIV status, geography and sex also have an 
important role in EBV associated Hodgkin lymphoma38, 39. 
The order of frequency of Hodgkin lymphoma associated with EBV is as 
follows40: 
 Mixed cellularity  -  70 percent 
 Lymphocyte depleted  -  50 percent 
 Nodular sclerosis   -  20 percent 
 Lymphocyte predominant  -  5 percent 
A study conducted by Rajalakshmi et al in Bangalore found that EBV positivity 
was found in 55 percent of HL cases. They also noticed lower Hasenclever 
prognostic score in HL patients affected with EBV than EBV negative 
patients41.  
A study conducted in Pediatrics department, AIIMS, New Delhi found that 91 
percent of children with Hodgkin lymphoma were positive for EBV virus42. 
Males, children below 10 years and mixed cellularity type are more commonly 
associated with EBV positive HL according to many studies43 . 
A study conducted by Elmir et al found that there is variation in the incidence 
of EBV associated HL in various Subtypes.  66 percent lymphocyte depleted 
type, 58 percent mixed cellularity, 45 percent nodular sclerosis and 25 percent   
lymphocyte predominant subtypes were associated with EBV infection4. 
The pathogenesis of EBV associated HL depends on many biological modifiers 
like age, social status, sex, geography and ethnicity. The background 
population composed of inflammatory infiltrate is different in EBV associated 
HL and non-EBV associated HL. This is due to the variation in the immune 
interaction caused by the EBV virus between the tumor and the host4. 
EBV associated HL accounts for 40 percent of total cases of HL and the 
association is more common in developing countries than developed countries 
with majority of the cases belonging to the mixed cellularity subtype44. 
A study conducted by Juliane et al, used conventional PCR method for the 
detection of EBV DNA and found that 43 percent of HL patients contain EBV 
DNA. 91 percent of positive cases showed positivity for both LMP1 by IHC 
and EBV DNA by conventional PCR method45. 
Earlier it was difficult to do research on HL and to use the molecular methods 
because the RS cells, which are the neoplastic cells are scattered in the tumor 
and their presence is also scanty. Hence methods like PCR, IHC and gene 
expression array are being used to study the various aspects of Hodgkin 
lymphoma which would overcome the abovesaid problems. 
A study conducted by Mueller et al found that EBV infected person had a 2 to 
4 fold increase in the risk of developing HL when compared with patients who 
did not have the infection46. 
 HL is more common in patients suffering from infectious mononucleosis and a 
mean time of 2.9 years is needed for HL to occur in a patient suffering from 
infectious mononucleosis.  It is postulated that this time is needed for various 
alterations to occur in the lymphocyte cell population47, 48.   
Men are more commonly infected with EBV than women patients and the rate 
of infection keeps increasing as the patient ages. Mixed cellularity subtype of 
HL is most commonly infected with EBV16. 
A study conducted by Swerdlow et al, found that EBV infected HL  is more 
common in mixed cellularity and lymphocyte depleted subtype, in children 
from low socioeconomic status, in males and more common in Asians than 
whites13. 
Genetic factors also play a role in the incidence of HL. Parental consanguinity 
was strongly associated with HL in a study conducted by Abramson et al who 
found a recessive pattern of inheritance. They also found that the family 
members of HL affected patients had a 3 to 9 fold increased risk49. 
The first degree relatives had a risk of three when compared to the controls. It 
was also found that the males have a higher risk than females and siblings are 
more prone for the disease in comparison to the offsprings and parents49. 
 Increased incidence of HL in patients suffering from infectious 
mononucleosis / past infection of IM. 
 Increased antibody production to EBV antigen in HL cases.  
 Presence of EBV gene products in RS cells.  
All these above said factors serve as an evidence for the role and involvement 
of EBV in the occurrence of HL. EBNA1, LMP1, 2 and EBER gene products 
are expressed in HL by EBV virus and have Type II latency. Gt10 also plays a 
role in HL but the mechanism is not clear50.   
EBV association is not equally seen in all subtypes of HL and is quite variable.  
It is positive in around 70 percent of mixed cellularity subtype, > 95 percent of 
lymphocyte depleted type, 10 to 40 percent in nodular sclerosis subtype. Most 
of the lymphocyte predominant HL is negative for EBV51.  
The reason for the occurrence of EBV associated HL in different age group is 
different. Primary infection is the cause for EBV positive HL in young children 
whereas in older population, it is the waning immunity which paves the way for 
the increased viral proliferation and oncogenesis29. 
BIOLOGICAL NATURE OF EBV INFECTION 
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LMP and EBER 
Measurement of tumor burden by various methods including 
immunohistochemistry, molecular ways are important in two perspectives 
namely:  
1. To make the correct diagnosis  
2. For targeted therapy52-55  
EBV nucleic acid as well as the protein present in the RS cell can be assayed 
by histochemical techniques. LMP and EBER are the common proteins which 
are measured.  LMP stands for Latent Membrane Protein and has Subtypes like 
LMP1, LMP2a and LMP2b. It is the protein which is expressed by EBV5. 
EBER is EBV encoded RNA which could be EBER1 or EBER2. EBV RNA 
can be detected by insitu hybridization. In tissue section, compared to LMP, 
EBER insitu hybridization is considered the best test to identify EBV56-61. 
EBER INTERPRETATION 
False positive results are because of non specific staining, cross reactivity with 
mucin, yeast and background lymphocytes. False negative staining is due to the 
RNA degradation. A control stain should be used to overcome this problem56, 
62.  But the reactive lymphocytes of infectious mononucleosis and lymphocytes 
in patients who are viral carrier do express LMP in their cytoplasm63, 64.   
A suitable control for EBER is U6 cellular transcript. EBER and U6 cellular 
transcript share similarities in relation to the size, intranuclear distribution and 
abundance65. The tumors which were positive for EBV at a particular time 
might become EBV negative when tested after a period of time by another 
method.  This is explained by the “hit and run hypothesis” which states that the 
EBV virus which was once present in the tumor could be subsequently lost66, 67. 
There are many molecular assays which have been developed to monitor the 
tumor burden in case of EBV related HL.   
Immunohistochemistry can also be used to identify the EBV virus infected 
Hodgkin lymphoma.  LMP is part of EBV and is usually expressed in the 
cytoplasm of the RS cells but the background lymphocytes do not usually 
express LMP in case of Hodgkin lymphoma68. 
The advantages of doing LMP over EBER hybridization are cost effectiveness 
and rapidness of the test result. LMP1 IHC marker can be used as a part of 
routine work up for the diagnosis of Hodgkin lymphoma5.  
LMP marker can be used on well fixed paraffin sections. Proper fixation of the 
tissue is important to avoid false positive result. False negativity is seen in case 
of tissues which have undergone decalcification. 
Currently both EBER and LMP are used as part of workup for Hodgkin 
lymphoma but there are no set guidelines for the correct interpretation as well 
as for the reliability.  
A study conducted by Gulley et al, found that the cytoplasm and the surface 
membrane of the RS cells were stained with LMP1 immunomarker, but not the 
nucleus. There was no expression of LMP in the background reactive 
lymphocytes. There was also variation in the intensity of staining in the RS 
cells which ranged from weak to strong with a granular character5.  
There could be nonspecific staining in the form of faint homogenous character 
and should not be considered as positive. This is often seen in the case of 
mummified tumor cells and fibroblast. 
Eosinophils and plasma cells which are seen in the background can also take up 
the stain occasionally. But both eosinophils and plasma cells can be made out 
not only based on the size and shape of the cell and nucleus but also by the 
granules present in the eosinophils and cartwheel chromatin seen in the plasma 
cells. The best method in such circumstances was to compare the IHC section 
with that of haematoxylin and eosin stained section to identify the correcT-cell 
population which is being studied.  
Gulley et al recommended using a positive and negative control slides.  
Positive slide is used to know if the system is working or not and to have it as a 
model to compare the color and granularity of true positive staining.  Negative 
control will aid in identifying non specific staining5. 
There are situations in which focal positivity of RS cells to EBER are seen i.e. 
not all the RS cells take up the stain. The reason for this partial staining is 
because of the focal preservation of the RNA. Hence an U6 stain should be 
done to know the area where the RNA is well preserved. EBER analysis can 
then be done only to this particular well preserved area to avoid partial or focal 
staining. They also noted non specific staining of LMP1 in the edges of the 
tissues which could be due to fixation artifact and this should be disregarded. 
Following guidelines were given for the interpretation of LMP1 stain and 
EBER insitu hybridization in relevance to Hodgkin lymphoma5. 
* It is important to differentiate RS cell from the reactive non tumor 
cells and hence a hematoxylin and eosin stained section should be 
analyzed before looking at the LMP1 or EBER staining.  
* Positive staining for LMP1 or EBER in a single RS cell is sufficient 
enough to make a diagnosis of EBV associated Hodgkin lymphoma. 
* The cytoplasm and the surface membrane of the RS cells show LMP1 
staining and appear granular. Staining in eosinophils, plasma cells, edge 
artifact and background staining should not be considered as true 
positive. 
* Adequate quality control of the whole immunohistochemistry 
procedure is needed.   
Lack of RNA in the RS cells cannot be directly correlated as an EBER negative 
case since there are many steps in processing during which the RNA could be 
destroyed. To avoid this, Gulley et al suggested using sterile water bath and 
using gloves to handle the slides so that there is no contact with bare hands. 
RNAse should be handled with care, adequate fixation of the tissue with either 
formalin or B5 and adequate size of the tissue biopsy as it is difficult to 
interpret small biopsies which have few RS cells5. 
Both formalin and B5 fixative could cause black precipitation that would 
obscure the chromogen to be read.   
While analyzing a slide one should use a medium to high power to screen the 
whole slide because some time the staining is only focal or weak. The focal or 
weak staining pattern could be due to the LMP1 down-regulation or the ability 
of our immune system to handle and destroy these foreign antigens. But the 
exact reason is not fully understood yet.   
Unequivocal cases can be diagnosed with LMP1 or EBER insitu hybridization 
but if the result is equivocal then a combination of H and E stain, LMP1 and 
EBER should be done simultaneously to come for a consensus result5.  
Infectious mononucleosis should be considered as a differential when many of 
the lymphocytes are positive for EBER5.   
EBV is made up of many products which are unique and have different sets of 
functions like LMP1, LMP2, EBNA1, 2, 3, EBER1, 2, EBNA-LP and BART 
or CST. 
 
EBNA1 
It plays a role in the replication of EBV genome and for its maintenance. The 
latent infection seen in EBV infection is also mainly due to EBNA1. It is a 
DNA specific binding protein and the viral episomes are segregated during 
mitosis by this product. Replication starts with the binding of EBNA1. It 
usually binds to the plasmid and this lead to the activation of host enzymes and 
replication of the virus69. 
EBNA2 
It is a transcriptional co-activator. It is the first protein to be detected after EBV 
infection. CD23 and cellular proto oncogene c-myc are up-regulated by 
EBNA2.  
EBNA2,3, EBNA LP, LMP1 and EBER1,2 are important for the 
immortalization in the affected cells by activating many genes70.   
EBNA LP 
It is also an early protein expressed during EBV infection.  EBNA2 and EBNA 
LP act together to inactivate p53 and retinoblastoma gene, which are the tumor 
suppressor genes leading on to the activation of cyclinD2. Cell fate is 
determined by an important pathway called the “Notch signaling pathway”. 
EBNA2 and EBNA LP play an important role in this notch signaling 
pathway71. 
EBNA 3A, 3B, 3C 
They have a role in transcription regulation. They also have a role in notch 
signaling pathway by their interaction with Cp binding factor 172. 
LMP1 
It is a viral protein which plays an important role in the pathogenesis and 
oncogenesis. The structure of LMP1 consists of six segments and a cytoplasmic 
tail. The segments are hydrophobic and the effector is present in the tail region. 
Aggregation of LMP1 happens in the plasma membrane in patches with the 
help of transmembrane segments and also by the NH2 terminus. 
Immortalization of EBV is mainly due to this aggregation.  BCL2 is an 
important anti-apoptotic gene and LMP1 causes an increase in the level of 
BCL2 leading to the inhibition of apoptosis and increased cell turnover.   
The cytoplasmic tail has the COOH terminal which combines with the TNF 
receptor associated death domain. Tumor necrosis factor receptor associated 
TRAF1 and TRAF2 factors like CD40 also interact in the same way and with 
the same factors and hence LMP1 is a mimicker of CD40.  
 There are two transformation effector sites namely 1 and 2.  TRAF binds to 
site 1 and death receptor associated with tumor necrosis factor binds to site 273.   
There are four signaling pathways involved in LMP1 function namely74: 
Nuclear factor B 
It is one of the important transcription factors. It plays a role in apoptosis and 
cell growth regulation. Many cytokines and lymphotoxin expression are 
controlled by this factor.  
Janus kinase/signal transducer 
There occurs integration of various factors like Janus kinase/signal transducer 
with the activator protein 1 transcriptor factor. 
P38 mitogen activated protein kinase 
It plays an important role in signaling and has a role in the activation of ATF2 
transcription factor.   
C-Jun NH2-terminal kinase 
Increased B-cell adhesion molecule expression and B-cell activation are mainly 
due to the above said various cascades which are linked with LMP1. The B-cell 
adhesion molecules are CD58, LFA1 and CD54 and the markers for B-cell 
activation are CD40, CD44, CD23, CD34 and HLA class II. The apoptosis 
caused by p53 is also averted by these interactions75. 
LMP2 
There are two types of proteins namely LMP-2A and LMP-2B which are coded 
by the LMP2 gene. LMP2 is also an integral membrane protein like LMP1. 
LMP2A and 2B are similar except the NH2 terminal domain 118 - residue 
domain which is seen in LMP2A and is not seen in LMP2B. Additionally 
LMP2A terminal domain is cytoplasmic. The latency seen in the EBV virus 
infection in the bone marrow is due to the LMP2. It has a role in the 
oncogenesis of Hodgkin lymphoma and nasopharyngeal carcinoma by 
mechanism not yet known76.   
EBV encoded RNA 1 and 2 
These RNA are uncapped RNA consisting of 167 nucleotides in EBER1 and 
172 nucleotides in EBER2.These RNA are non-coding and non-
polyadenylated. 
 Most of the EBV infected cells express EBER1 and 2 in abundance. Few types 
of hepatocellular carcinoma and oral hairy leukoplakia do not express EBER.  
EBER has a role in the uptake of autocrine growth factors. It plays a role in 
Burkitt’s lymphoma to sustain the malignant phenotype. All types of latency 
involve the expression of EBER1 and 277.   
Complementary strand transcript 
It is also called Bam A rightward transcript. There is an increased amount of 
this transcript in nasopharyngeal carcinoma. It is also involved in notch 
signaling.  
Hodgkin lymphoma patients are found to have immunologic deficiency and 
impaired immune response and this is revealed by the increased LMP1 
expression in the RS cells.   
AN OVERVIEW OF EBV PRODUCTS AND FUNCTIONS 
LMP1  EBV immortalization  
 Similar to CD40 
 Inhibits apoptosis by increasing the level of BCL2 and a20. 
LMP2 ( A,B)  Role in latency  
 HL and Nasopharyngeal oncogenesis 
EBNA1  EBV immortalization 
 EBV genome replication 
EBNA2  Transcription co-activator 
EBNA3 (A,B,C)  CBF1 interaction 
 EBV immortalization 
EBER (1,2)  Involved in latency 
 Oncogenesis of Burkitt’s lymphoma 
 Abundant expression in all EBV infected cells 
EBNA-LP  Notch signaling 
 Inactivates Rb and p53 genes 
CST or BART  Oncogenesis of nasopharyngeal carcinoma 
 Notch signaling 
A study conducted by Elmir et al found that the detection rate of EBV 
associated HL by LMP1 IHC method was 23 percent whereas insitu 
hybridization method employed to detect EBV RNA was 48 percent4. 
90 percent of cases of EBV associated HL were detected by the conventional 
PCR method. Specificity was more and sensitivity was less with quantitative 
PCR. Quantitative PCR which is used to measure the viral load is more 
beneficial compared to the conventional PCR78. 
LMP1 acts as a receptor for tumor necrosis factor and many signaling pathways 
like B, which is a nuclear factor, are activated by LMP1 causing growth 
transformation. 
Ki-67 
All the proliferating cells in the cell cycle express Ki-67. It is a nuclear as well 
as a nucleolar antigen present in the cell during G1, S, G2 and M phases of cell 
cycle. The Ki-67 index or the proliferation index is obtained by dividing the 
cells positive for Ki-67 to the total number of cells present in the tissue. The 
active growth fraction in a tumor is called the Ki-67 proliferation index. It is 
said that, more the Ki-67 index, greater is the grade of the tumor. Similarly, 
high Ki-67 index is associated with increased aggressiveness of the tumor. Ki-
67 index is an important prognostic and predictive factor in many 
malignancies6. 
There is no specific cutoff to differentiate high and low proliferation index in 
case of lymphomas. But a study conducted by Mehrdad et al divided Ki-67 
index as low or high based on a cutoff of 65%. Tumors expressing Ki-67 <65% 
were termed as low proliferating tumors while those having >65% staining 
were called as lymphomas with high proliferative index79. 
Different studies have used different cutoffs to define high and low index 
ranging from as low as 20% to as high as 80%. Hence it is essential to 
standardize and fix a cutoff for defining high and low Ki-67 index in 
lymphomas for uniformity and universality in reporting Ki-67. 
PHARMACOLOGICAL TREATMENT  
Though lot of studies are done regarding the role of EBV in HL, the treatment 
of EBV associated HL is not satisfactory. Various methods are tried, like the 
use of antivirals, immunologic modulators and the usage of monoclonal 
antibodies80. 
ANTIVIRALS 
Though many drugs are being used, the reproducibility is difficult. The most 
commonly used antivirals are Ganciclovir, Foscarnet and Acyclovir. These 
drugs have a broad spectrum and are used against Herpes virus, 
Cytomegalovirus and EBV. 
In case of HIV associated EBV positive HL, the antiretroviral agent 
Zidovudine can be used in combination with Interferon alpha. This 
combination causes the apoptosis of the cells infected with EBV. 
Apart from these pharmacological conventional drugs, many non-conventional 
preparations are also used for the treatment of EBV positive HL and are found 
to be beneficial. Plant extracts namely flavones are being used to block the 
antigen activation. Similarly flavanoid derivatives which are prepared from the 
herbs are found to have anti - EBV activity81. 
IMMUNOTHERAPY 
The basic underlying pathology in EBV associated HL is the 
immunosupression. It plays an important role in causing tumorogenesis of HL. 
The above said antiviral drugs do not have any role in correcting the underlying 
immunosupression. Hence immunotherapy is also needed. EBV specific CTL 
are used in immunotherapy. The disadvantages of immunotherapy are labor 
intensive and time consuming. CTL can be obtained from healthy donor and 
can be directly infused into the affected person or it can be cultured invitro and 
can be proliferated. This proliferated CTL can be infused into the patients. This 
helps in increasing the immunity of the patient. Around 8 to 12 weeks are 
needed for the production of the CTL which are specific for EBV from the 
donor. This method of immunotherapy can be used either for prophylaxis or for 
the eradication of the disease82. 
MONOCLONAL ANTIBODY 
Rituximab is a monoclonal antibody which is specific for CD20. Any CD20 
expressing lymphoma can be treated with Rituximab. It has been found to be 
effective in EBV associated HL. Anti IL-6 monoclonal antibodies are also 
being used now because IL-6 is a growth factor expressed in many 
lymphomas82. 
 
 
     
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
The study started after obtaining clearance from Institutional Human Ethics 
Committee (extensive reviewing of literature was done about the association of 
EBV with HL. The specific IHC marker for the identification of EBV infection 
in HL was found to be LMP1 marker and the details about the availability and 
the cost of the marker was done. A study protocol was created and was 
submitted to IHEC). 
After obtaining the clearance, all cases of HL reported in PSG IMS & R from 
the department of Pathology were identified from the histopathology registers 
which are archived in the Pathology department. It was a retrospective study 
and the study period included January 2011 to December 2015. All the cases of 
HL diagnosed during the above said five years were taken for evaluation. The 
blocks of these cases were retrieved from the archives of Pathology; PSG 
IMS&R. Proven cases of HL with the non availability of the blocks (blocks 
which were taken for treatment purpose and second opinion) were excluded 
from the study. Also excluded were the blocks with inadequate tissue as further 
work up cannot be done on such blocks. 
First, the hematoxylin and eosin section of each case archived was analyzed to 
assess the pattern, morphology, type of RS cells and background population. 
The archived H and E sections were accompanied by the IHC markers in most 
of the cases. The markers commonly employed were CD 45, CD20, CD3, 
CD15 and CD30.  Few of the cases had additional work up for EMA and ALK.   
Few cases were not worked up and the above said common panel of markers 
was run for those cases to complete the basic work up. Many of the cases had 
two or more blocks. Hence H and E section of each block was studied and the 
block with maximum tumor density was chosen in collaboration with H and E 
section. Two sections from each block were cut, one for LMP1 marker and the 
other for Ki-67. 
The two main steps involved in immunohistochemistry are  
 Binding of specific epitope seen in the tissue with the primary antibody 
 Detection of primary antibody bound to secondary antibody by the 
usage of chromogen using calorimetric principle. 
The five important steps involved in an IHC procedure are83 
 Retrieval of antigen 
 Usage of primary antibody 
 Addition of secondary antibody 
 Use of chromogen 
 Counter staining and mounting 
Retrieval of antigen is very important as formalin fixation masks the epitope by 
cross linking. Unmasking of these antigens can be done by many methods like 
usage of microwave Owen, pressure cooker or by proteolytic digestion. 
We employed the pressure cooker method which produces both heat and 
pressure enabling full expression of masked antigens. 
Reagents employed 
 EDTA buffer with a pH of 9 
 3% hydrogen peroxide (H2O2) 
 Casein in PBS with 15 mM sodium azide 
 0.01M phosphate buffered saline having a pH of 7.6 
Endogenous peroxidase causes nonspecific background staining and this is 
prevented by the usage of hydrogen peroxide which is mixed in distilled water. 
Casein is used as a blocking reagent and prevents non specific protein binding. 
Ready to use primary antibodies were employed in our study. 
EBV antibody used in our study is a mouse monoclonal antibody. It is prepared 
from cell culture. The supernatant present in the cell culture undergoes various 
processes like           concentration          dialysis   filtration      
sterilization and dilution in a buffer with a pH of 7.5. BSA and sodium azide 
are used as preservatives. The marker was stored at 4degree Celsius in the 
laboratory refrigerator during the study period. 
Poly HRP reagent 
It is a combination of HRP enzyme with anti mouse and anti rabbit IgG 
complex. 
3, 3’diamino benzidine tetra hydrochloride (DAB) is the chromogen employed 
in our study. The color is detected by calorimetric principle. DAB gives a 
brown color. 
The last step is counterstaining with Harris hematoxylin and mounting with 
DPX (distrene dibutyl phthalate xylene) 
Sections grading system was used to score the number of neoplastic cells 
positive for LMP1 as follows84 
 none seen in the section 
 Presence of positive cells but rare and not exceeding 25% 
 26% to 50% positive cells 
 51% to 75% positive cells 
 76% to 100% positive cells 
 
 
SUMMARY OF THE IHC PROCEDURE EMPLOYED IN OUR STUDY 
Two slides for each case cut 
Deparaffinisation of the slides 
Usage of graded alcohol for hydration 
Antigen retrieval by placing the slides in pressure cooker for a period of 10 min 
using EDTA buffer at a pH of 9 
Cooling the slides in tap water for 20 min 
5 min wash in PBS buffer 
Immersion of slides in 0.3% H2O2 x 20 min 
Wash in PBS buffer x 3 times (5 min each) 
Slides in blocking solution x 10 min 
Wash in PBS buffer x 3 times (5 min each) 
Incubation of slides with primary antibody (10 min) 
Wash in PBS buffer x 3 times (5 min each) 
Incubation with HRP reagent x 30 min 
Wash in PBS buffer x 3 times (5 min each) 
DAB application (8 min) 
Wash in PBS buffer x 3 times (5 min each) 
Counterstaining with Harris Hematoxylin x 1 min 
Wash in tap water 
Clearance with xylene  
Mounting the slides with DPX 
Identification of Hodgkin lymphoma cases through histopathology register 
(January 2010 – December 2015) 
             
Blocks retrieved from the archives in histopathology laboratory 
  
INCLUDED   EXCLUDED 
H & E sections carefully analyzed  blocks with  inadequate material/ 
with the corresponding panel of markers  blocks taken outside for treatment                                      
purpose 
         
Morphologic diagnosis reconfirmed if marker study not done previously 
 
Cases with 2 or more blocks                                         
 
H & E section analyzed and block of the section     done afresh 
with maximum tumor density chosen 
 
                  2 sections cut 
     
     LMP 1   Ki - 67 
 
   Analyzed with H&E section as the base 
The various markers used, company, clone, antibody type, control and 
isotype 
Marker Localization Isotype Clone Control Company Antibody 
type 
LMP1 Cytoplasm IgG1 CS 1-4 HL infected 
with EBV  
Bio SB Mouse 
monoclonal 
CD15 Cytoplasm & 
membrane 
IgG EP 273 Normal kidney DAKO Rabbit 
monoclonal 
CD30 Cytoplasm & 
membrane 
IgG1 Ber-H2 Hodgkin 
disease 
Path  n Situ Mouse 
monoclonal 
EMA Cytoplasm & 
membrane 
IgG2/K E29 Breast ductal 
carcinoma 
Path n Situ Mouse 
monoclonal 
ALK Cytoplasm & 
membrane 
IgG2b OR1A4 Anaplastic 
large cell 
lymphoma 
Path n Situ Mouse 
monoclonal 
CD3 Cytoplasm & 
membrane 
NA Polyclonal tonsil Path n Situ Rabbit 
monoclonal 
CD20 Cell membrane IgG2a L26 tonsil Path n Situ Mouse 
monoclonal 
RESULTS AND OBSERVATIONS 
Table 1:- AGE WISE DISTRIBUTION OF EBV POSITIVITY IN 
HODGKIN LYMPHOMA 
 
  
AGE GROUP 
(years) 
NO OF CASES OF HODGKIN 
LYMPHOMA (34 cases) 
EBV POSITIVITY  
(22 cases) 
0- 10 1 1 
11-20 11 5 
21-30 5 2 
31-40 4 3 
41-50 4 3 
51-60 5 5 
61-70 2 1 
71-80 2 2 
Table 2. COMPARISON BETWEEN EBV POSITIVE & EBV 
NEGATIVE HODGKIN LYMPHOMA IN VARIOUS AGE GROUPS 
    AGE GROUP       EBV POSITIVE        EBV NEGATIVE 
0- 10 years 1 0 
11-20 5 6 
21-30 2 3 
31-40 3 1 
41-50 3 1 
51-60 5 0 
61-70 1 1 
71-80 2 0 
 
Table 3.1. DISTRIBUTION OF EBV POSITIVE HODGKIN 
LYMPHOMA ACCORDING TO GENDER 
AGE GROUP MALES FEMALES 
0- 10 years 1 - 
11-20 3 2 
21-30 2 - 
31-40 2 1 
41-50 3 - 
51-60 4 1 
61-70 1 - 
71-80 2 - 
 
 
Table 3.2. ASSOCIATION BETWEEN GENDER AND EBV 
POSITIVITY IN HODGKIN LYMPHOMA 
Test Used Value P value Significance 
Yates chi square Value=.0001 P value= .974 Not significant 
Phi correlation 
coefficient 
Value=.081 P value = .638 Not significant 
 
3.1. SEX WISE DISTRIBUTION OF HODGKIN LYMPHOMA 
 
 
3.2. DISTRIBUTION OF EBV POSITIVE HODGKIN LYMPHOMA 
ACCORDING TO GENDER 
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Table 4. FREQUENCY OF HODGKINS LYMPHOMA IN VARIOUS 
SUB-TYPES 
 
SUBTYPE NO OF CASES PERCENTAGE 
MIXED CELLULARITY 16 47% 
NODULAR SCLEROSIS 12 35% 
LYMPHOCYTE RICH - - 
LYMPHOCYTE DEPLETED 3 9% 
LYMPHOCYTE 
PREDOMINANT 
3 9% 
 
 
 
 
Table 5. PERCENTAGE OF EBV POSTIVE PATIENTS IN EACH 
HISTOLOGICAL SUBTYPE 
 
 
 
 
Table 6. CLINICAL STAGE FOR EBV ASSOCIATED HODGKIN 
LYMPHOMA ACCORDING TO ANN ARBOR CLASSIFICATION 
SUBTYPE PERCENTAGE 
Mixed cellularity 50% 
Nodular sclerosis 27% 
Lymphocyte depleted 14% 
Lymphocyte predominant 9% 
STAGE EBV POSITIVE CASES EBV NEGATIVE CASES 
IA - - 
IB 1 - 
IIA 1 1 
IIB - 3 
IIIA 1 2 
IIIB 2 1 
IV - - 
 
 
 
 
 
 
 
 
 
 
 
 
 
Staging work up was done only for 12 patients 
 
0
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1
1.5
2
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EBV POSITIVE 
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6.CLINICAL STAGE FOR EBV ASSOCIATED HOGKIN LYMPHOMA 
Table 7.1. IHC MARKERS ANALYSIS 
IHC MARKER NUMBER OF CASES POSITIVE 
CD15 21/34 
CD30 31/34 
LMP1 22/34 
 
 
Tables 7.2.COEXISTENCE OF CD15,CD30 & LMP1 EXPRESSION 
 
IHC MARKER NUMBER OF CASES 
POSITIVE 
CD15+ CD30 19 
CD15+ LMP1 14 
CD30+LMP1 20 
CD15+CD30+LMP1 13 
 
CD15
CD 30
19 14
13
20
LMP1
7.COEXISTENCE OF CD15, CD30 & LMP1 EXPRESSION 
 
 
 
 
 
Thirteen cases were positive for all the three markers namely CD15, CD30 and 
LMP1 
 
 
 
 
Table 8. Ki-67 LEVELS IN HODGKIN LYMPHOMA IN RELATION TO 
EBV 
 
EBV      High Ki-67               Low Ki-67 
positive 15 7 
negative 4 8 
 
 
8. Ki- 67 LEVELS IN HODGKIN LYMPHOMA IN RELATION TO EBV 
EBV 
Table 9. Ki-67 INDEX IN VARIOUS SUBTYPES 
SUBTYPES HIGH Ki-67 LOW Ki-67 
MIXED CELLULARITY 9 7 
NODULAR SCLEROSIS 7 5 
LYMPHOCYTE 
DEPLETED 2 1 
LYMPHOCYTE 
PREDOMINANT 1 2 
 
 
 
 
Table 10. CORRELATION BETWEEN LMP1 GRADING AND 
HIGH/LOW Ki-67 INDEX 
 
Correlation 
 
rpb 
 
P value 
 
significance 
 
Biserial 
correlation 
coefficient 
 
rpb value= .540** 
 
P = .001 
 
HIGHLY 
SIGNIFICANT 
 
** Correlation is significant at the 0.01 level (2-tailed). 
 
 
 
 
THIS IS A GRAPHICAL REPRESENTATION OF THE POSITIVE 
CORRELATION BETWEEN LMP 1 GRADING AND HIGH Ki-67 
INDEX 
CHARACTERISTICS OF 34 PATIENTS OF HODGKIN LYMPHOMA 
MEDIAN AGE - 31.5 Yrs 
RANGE 
7 - 77 YRS 
SEX 
Males- 27/34 (79%) 
Females - 7/34 (21%) 
STAGE (ANN ARBOR METHOD) 
Localized- 3/12 (25%) 
Disseminated -9/12 (75%) 
(Localized disease involves stage IA, IB, IIA and  
Disseminated disease involves stage IIB, IIIA, IIIB, IVA, IVB) 
HIV POSITIVE STATUS   - 1/34 
NUMBER OF CASES IN EACH HISTOPATHOLOGIC SUBTYPE 
Mixed cellularity - 16 (47%) 
Nodular sclerosis - 12 (35%) 
Lymphocyte depleted - 3 (9%) 
Lymphocyte predominant- 3 (9%) 
LMP 1 protein 
Positivity – 22/34 CASES 
 
HODGKIN LYMPHOMA TYPE EBV POSITIVITY 
 
CLASSICAL HODGKIN LYMPHOMA 
 
22/31 
 
LYMPHOCYTE PREDOMINANT 
HODGKIN LYMPHOMA 
2/3 
 
 
 
 
 
 Fig 1: NODULAR SCLEROSIS SUBTYPE (H&E STAIN, 40x) 
 
Fig 2: SYNCYTIAL VARIANT OF NODULAR SCLEROSIS SUBTYPE 
(H&E STAIN, 400x) 
Fig 3: MIXED CELLULARITY SUBTYPE (H&E, 400x) 
 
Fig 4: LYMPHOCYTE DEPLETED SUBTYPE (H&E, 400x)
 Fig 5: LYMPHOCYTE PREDOMINANT SUBTYPE (H&E, 400x) 
 
Fig 6: CD15 POSITIVITY IN THE RS CELLS (IHC, 400x) 
Fig 7: CD30 POSITIVITY IN THE RS CELLS (IHC, 400x) 
Fig 8: RS CELLS POSITIVE FOR CD20 IN LYMPHOCYTE 
PREDOMINANT HODGKIN LYMPHOMA (IHC, 400x) 
Fig 9: CD3 POSITIVITY IN THE BACKGROUND LYMPHOCYTES 
FORMING ROSETTES AROUND THE RS CELLS (IHC, 400x) 
Fig 10: LATENT MEMBRANE PROTEIN 1(LMP1) 2+ POSITIVITY 
(IHC, 400x) 
Fig 11: LATENT MEMBRANE PROTEIN 1(LMP1) 4+ POSITIVITY 
(IHC, 400x) 
 
Fig 12: HIGH Ki-67 EXPRESSION IN THE RS CELLS (IHC, 400x) 
DISCUSSION 
Hodgkin lymphoma is a distinct hematological neoplasm which is still an 
enigma to understand in spite of umpteen number of research happening 
globally regarding this disease. It has the following characteristic features  
 They commonly arise from the cervical lymph node 
 Manifestation of the disease is usually seen in young adults 
 The neoplastic cells which are the Reed Sternberg cells are seen only in 
minority and the predominant population is the reactive mixed 
inflammatory cells which include lymphocytes, plasma cells and 
eosinophils in the background 
 Rossetting of the background T lymphocytes around the neoplastic RS 
cells. 
National cancer institute surveillance, epidemiology and end results program 
have estimated the new cases of HL in 2016 to be 8500 i.e. 0.5% of all the new 
cases of cancer diagnosis. The prevalence of this cancer was estimated to be 
193,545 people in US in 2013. 
According to Globocon 2012 data, incidence of HL among Indian males was 
5,677/lakh and 2,938/lakh among Indian females. Based on our hospital data, 
around 10 cases of HL have been reported every year. We aimed at studying 
the clinicopathological profile and expression of EBV antigens in Hodgkin 
lymphomas diagnosed in our department over the last 5 years. After excluding 
the cases which did not have the paraffin blocks due to the transfer of patients 
to higher cancer institutes for treatment purpose, we were able to retrieve 
blocks of 34 cases for our study purpose. It was a retrospective descriptive 
study. 
As per the data obtained and analyzed, distinct bimodal age distribution was 
seen in cases of Hodgkin lymphoma. Our study revealed the first peak between 
11 - 20 years and the second peak between 51- 60 years. This finding is 
consistent with many studies which showed a bimodal pattern of age 
distribution in case of Hodgkin lymphoma85.   
Our study included cases in a wide age group ranging from 7 yrs to 77 years. 
The median age of occurrence of HL in our study was 31.5 years. This was 
similar to the study conducted by Juliane et al who found a median age of 28 
years45 and a study conducted by Elmir et al who found a median age of 38.5 
years4. 
Males are more commonly affected by Hodgkin lymphoma compared to 
females according to the study conducted by Juliane et al45 and Zahra et al11. 
Our study was in concordance with the above studies. 27 males and 7 females 
were affected with Hodgkin lymphoma in our study which accounts for 79% 
and 21% respectively. 
The male: female ratio was 3.8: 1 which is slightly higher than study conducted 
by Mac Mohan et al who found a male: female ratio of 2:110. 
HL most commonly involves the cervical lymph nodes and the spread is 
through contiguous nodes unlike NHL which involves extra nodal sites and 
peripheral nodes with unpredictable spread9. In our study also, the cervical 
lymph nodes were most commonly affected followed by inguinal lymph nodes. 
Out of the 34 cases studied, 33 were nodal and one case was extra nodal 
(omentum). 
The occurrence of Hodgkin lymphoma in HIV positive patients represent one 
of the most common types of AIDS defining illness and its incidence is on a 
rise post “highly active antiretroviral therapy” or HAART era86. There is a 
tenfold increase in the incidence of Hodgkin lymphoma in HIV infected 
patients. Of the 34 cases we studied, one case was positive for HIV87. 
According to WHO classification, Hodgkin lymphoma is broadly divided in to 
two categories namely3 
 Classical HL 
 Lymphocyte predominant HL 
Classical Hodgkin lymphoma includes 
 Mixed cellularity 
 Nodular sclerosis 
 Lymphocyte depleted 
 Lymphocyte rich 
Lymphocyte predominant type is further divided in to two namely  
 Nodular LPHL 
 Diffuse LPH 
World over, nodular sclerosis subtype is the commonest followed by mixed 
cellularity subtype. But in developing countries like India, there is an increased 
incidence of mixed cellularity subtype compared to nodular sclerosis. Our 
study also revealed increased frequency of mixed cellularity subtype. It 
constituted the major bulk of the case load.16 out of 34 cases (47%) were of 
mixed cellularity subtype, followed by the nodular sclerosis subtype accounting 
for 12/34 cases (35%). 3 cases belong to lymphocyte depleted subtype.  
Lymphocyte rich subtype was not reported during the study period. 3 cases of 
Nodular lymphocyte predominant subtype were reported. 
Totally, classical Hodgkin lymphoma accounts for 31 cases (91%) and 
lymphocyte predominant subtype for 3 cases (9%) of the 34 cases reported 
during the study period. 
                    
                
 
Frequency of Hodgkin lymphoma subtypes 
Subtype WHO STUDY OUR STUDY 
Nodular sclerosis 36% 35% 
Mixed cellularity 51% 47% 
Lymphocyte depleted 5% 9% 
Lymphocyte rich 7% - 
Lymphocyte 
predominant 5% 9% 
 
Our findings were consistent with the WHO study. 
 One of the cases had a coexistent Granulomatous lesion along with Hodgkin 
lymphoma. Syncytial variant is a variant of Nodular Sclerosis subtype of 
Hodgkin lymphoma which is characterized by increase in the lacunar cells and 
clustering of lacunar cells which could be confused with a metastatic 
carcinoma with clear cell changes. One case of Syncytial variant was reported 
during the study period. 
 Hodgkin lymphoma is a unique neoplasm as the neoplastic cells constitute 
only a minority of the total cell population. The RS cells which have a 
characteristic binucleation with prominent eosinophilic nucleoli are not 
frequently seen but its variants like lacunar cell, popcorn cell and mummified 
cells are seen and are called RS like cells. The RS cells in classical HL exhibit 
a similar phenotype but the RS cells in lymphocyte predominant type exhibits a 
B-cell phenotype and hence classified as a separate entity2. 
The neoplastic RS cells are positive for CD15 and CD30. CD15 is relatively a 
specific marker for HL while CD30 is a sensitive marker1. 
We employed various markers like CD15, CD30, CD20, CD3, CD20, EMA 
and ALK for our study. 
The neoplastic cells were positive for CD15, CD30, CD20, EMA (CD20 and 
EMA were positive in LPHL only) and were negative for CD3.There was a 
strong membrane positivity for CD20 in all the three cases of nodular LPHL. 
 In our study CD15 expression was seen in 21/34 cases  and CD30 expression 
in 31/34 cases accounting for 62% and 91 % respectively proving CD15 to be a 
specific marker and CD30 to be a sensitive marker. These findings are 
consistent with the studies conducted by Haresh et al, who found CD15 
expression in 85% of cases of HL while CD30 was almost expressed 
universally87. Hsu et al found CD15 expression in 85 to 90% of cases and 
Chang et al found 89% positivity with CD30 antigen1. 
The background lymphocytes are predominantly of T-cell lineage and are CD3 
positive. A characteristic finding is the rossetting of the T-cells around the 
large neoplastic RS cells2. All our cases studied showed a similar pattern with 
CD3. 
Epstein - Barr virus is a herpes virus which is present worldwide in almost all 
human population and persists as a lifelong asymptomatic infection. It 
predominantly affects the T lymphocytes. EBV is an important etiological 
factor in many lymphoid and epithelial malignancies. The exact role of EBV in 
Hodgkin disease is not fully known yet. But there are strong evidences to show 
a fourfold rise in the incidence of HL in patients who had a prior history of 
infectious mononucleosis and the identification of EBV episome in the RS 
cells. 
EBV expresses various gene products which are called as the latent proteins. 
They include EBNA 1, 2, 3, EBNA LP and latent membrane protein LMP 1, 2. 
In our study LMP1 expression was studied as LMP1 is the main transforming 
factor seen in case of EBV associated HL. LMP1 has many roles like 
pleiotropic effects, activation of signaling pathway and belongs to the tumor 
necrosis factor receptor super family88. 
Based on the EBV status, Hodgkin lymphoma is grouped under three 
categories namely89 
 Paediatric HL - EBV positive and are of mixed cellularity subtype 
 HL occurring in young adults - EBV negative and are of nodular 
sclerosis type 
 HL occurring in older adults  - EBV positive and mixed cellularity type 
Many studies have found a strong relationship and association of EBV with 
Hodgkin lymphoma. Our study found that the neoplastic RS cells seen in HL 
were immunohistochemically positive for LMP 1 in 22/34 cases which account 
for 66%. This is in concordance with the study conducted by Veronique et al 
who found EBV positivity in 55% of HL cases90. The background lymphocytic 
infiltrate were negative for LMP 1 immunohistochemistry. Our study also 
found that almost 100% of cases of HL occurring in late adulthood were 
positive for EBV. 
There was not much variation in the expression of EBV in various sexes. EBV 
association was slightly more common in the males (67%) compared to 
females (57%). Similar findings were obtained by studies conducted by 
Swerlow et al13, Flavell et al20 and Veronique et al90. 
There was a significant variation in the expression of EBV in various subtypes. 
Mixed cellularity subtype had the maximum EBV expression with 11/16 cases 
accounting for 69%. This was followed by nodular sclerosis subtype where six 
out of 12 cases were positive (50%). All the lymphocyte depleted cases 3 out of 
3 were positive for EBV (100%). 2/3 cases of lymphocyte predominant subtype 
were EBV positive. 
Studies conducted by Veronique et al90 and Zahra et al11 also found mixed 
cellularity subtype to be the most common subtype to be associated with EBV. 
EBV EXPRESSION IN VARIOUS SUBTYPES OF HODGKIN 
LYMPHOMA 
SUBTYPE ELMIR ET AL4 BROUSSET ET 
AL58 
OUR STUDY 
Nodular sclerosis 66.7% 15-30% 50% 
Mixed cellularity 25.6% 70% 69% 
Lymphocyte 
depleted 
5.1%  100% 
Lymphocyte rich                - 
      
    NEGLIGIBLE 
               - 
Lymphocyte 
predominant 
            2.6%              67% 
 
We had one case of Hodgkin lymphoma which was associated with HIV. There 
was a strong EBV expression in this case and a LMP score of 4+ was given as 
almost 100% of RS cells were positive for LMP1. This is in concordance with 
the study conducted by Glaser et al who found strong associations of EBV 
infection in HIV infected patients with HL14. They are more commonly 
associated with B symptoms and extra nodal involvement. 
Ki-67 is a nuclear as well as a nucleolar antigen which is expressed in all the 
proliferating cells during G1, S, G2 and M phase of cell cycle. Ki-67 
proliferation index denotes active growth fraction present in the tumor. Ki-67 is 
being used as a prognostic and predictive marker in many malignancies. But 
there is no set strict cutoff for defining Ki-67 index as high or low in 
lymphomas. We took a cutoff of 65% to define Ki-67 expression as high or 
low. This cutoff of 65% was chosen based on the study conducted by Mehrdad 
et al who found a worse survival in patients having a high Ki-67 index79. 
But various studies have used a cutoff ranging from as low as 20% to as high as 
80%. Hence there is inconsistency regarding the prognostic implication of               
Ki-67. 
High Ki-67 index was seen in 19/34 cases (56%) and low Ki-67 index in 15 
cases (44%). 15 of the 27 males studied with HL had a high Ki-67 index (56%) 
and 4 out of 7 females (57%) with HL had a high Ki-67 index. There was no 
difference in the Ki-67 expression among males and females. This is consistent 
with the study conducted by Mehrdad et al who found no correlation between 
sex and Ki-6779. In EBV positive cases, high Ki-67 index was seen in 15/22 
cases (68%) and low Ki-67 index seen in 7/22 cases (32%) 
The percentage of cases with high Ki-67 expression in EBV positive HL 
subtypes is 
Mixed cellularity -73% 
Nodular sclerosis -67% 
Lymphocyte depleted - 50 % 
Lymphocyte predominant - 67% 
Maximum cases with high Ki-67 index was seen in mixed cellularity subtype 
(73%) which is consistent with the study conducted by Elham et al who also 
found increased Ki-67 expression in mixed cellularity subtype6. Very high Ki-
67 index was seen in HIV positive patient with Hodgkin lymphoma nearing 
almost 100%. 
Hasenclever prognostic score is an international prognostic score used to 
predict the outcome of lymphomas based on various parameters like age, sex, 
hemoglobin level, albumin, Ann Arbor staging, WBC count and lymphocyte 
count21. But this scoring could not be done in our study due to lack of follow up 
of cases as few cases went to higher cancer centers for further management. 
Combining Ki-67 index with Hasenclever index would help in predicting the 
outcome of the disease better which would lead to a more effective patient 
management. 
Staging workup and regular follow up were done only for 12 out of 34 cases of 
Hodgkin lymphoma, due to various reasons like financial constraints, referral 
to higher centers for treatment etc. Of the 12 cases which was worked up, 3 
belonged to localized disease category (stage IA, IB, IIA in Ann arbor staging 
were considered localized) while 9 cases were disseminated (stage IIB, IIIA, B, 
IV A,B) 
Eleven cases were given standard dose of ABVD regimen (Adriamycin 
(doxorubicin), Bleomycin, Vinblastine and Dacarbacine) for six cycles and 
follow up CT scan did not show any residual disease. 
One pregnant woman was diagnosed to have Hodgkin lymphoma stage III and 
was given 12 cycles of ABVD. One patient had residual disease in the follow 
up CT scan after six cycles of ABVD and was planned for radiotherapy.
LIMITATIONS 
1. EBV expression in lymphocyte rich subtype of Hodgkin lymphoma could 
not be studied as there was no case reported during the study period. 
2. EBV expression in non - Hodgkin lymphoma was not studied for 
comparison. 
3. LMP1 antigen was employed in our study for detecting EBV 
immunohistochemically. Combining this with EBER insitu hybridization 
would have increased the sensitivity of detection of EBV. 
4. Cutoff for defining Ki-67 proliferation index as high or low is still arbitrary 
in lymphomas and a fixed definitive cutoff would help in better 
interpretation of Ki-67. 
5.  As many patients could not be followed up due to various reasons, the high 
Ki-67 expression with the clinical outcome could not be elaborately studied. 
6. The use of Ki-67 and Hasenclever index as prognostic as well as predictive 
marker needs to be studied further. 
 
 
 
 
SUMMARY AND CONCLUSIONS 
 LMP 1 positivity was seen in 22 out of 34 cases studied. 
 Maximum EBV expression was seen in mixed cellularity subtype (50%) and 
nodular sclerosis subtype showed 27% positivity. 
 There was no significant gender predilection in EBV expression. 
 CD15, CD30 and LMP1 were positive in 13 cases. 
 EBV expression and Ki-67 proliferative index had a statistically significant 
correlation. 
 High Ki-67 index was more commonly seen in EBV associated Hodgkin 
lymphoma. 
 Although staging workup was not done on all cases, available data showed a 
high expression of EBV and Ki-67 in stage III and stage IV tumor. 
 Syncytial variant of nodular sclerosis, lymphocyte depleted subtype and HIV 
positivity which are associated with poor prognosis showed increased EBV 
expression and high Ki-67 index. 
Hence our study justifies the role of EBV in the oncogenesis of Hodgkin 
lymphoma. More elaborate and extensive studies are warranted to further 
emphasize this theory. Days would not be far off for a targeted therapy and an 
effective vaccine for EBV that would prevent primary infection or modulate its 
course leading to the reduction in the incidence of Hodgkin lymphoma, similar 
to the reduction of cervical cancer and hepatoma after HPV vaccine and 
hepatitis vaccine.   
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MASTER CHART 
SNO BIOPSY NUMBER SITE DIAGNOSIS AGE SEX CD45 CD15 CD30 CD20 OTHERS LMP1 Ki-67 
1 1112/11 inguinal LN MC 37 M - + + - ALK - ++ high 
EMA - 
2 1425/11 mesentric LN NS 55 M - + + - ALK - ++ high 
EMA - 
3 3005/11 cervical LN MC 14 M - - + - ND - low 
4 3825/11 cervical LN NS 28 M - + + - ND +++ high 
5 3858/11 cervical LN MC 11 M - - + - ND +++ high 
6 4474/11 cervical LN NS 16 M - + + - ND + low 
7 4566/11 inguinal LN MC 16 F - + + - ND + low 
8 1251/12 Submandibular 
LN 
Nodular LP 33 M + - - + occasional EMA +vity + low 
9 3986/12 cervical LN Nodular LP 11 M + - - + few EMA + cells + high 
10 4331/12 cervical LN MC 16 F - + + - ND - low 
11 1548/13 cervical LN LD 55 M - + +   ND ++ high 
12 2076/13 supraclavicular 
LN 
MC 23 F - - + - ND - high 
13 2824/13 cervical LN NS  47 M - - + - ALK- - low 
EMA- 
14 3919/13 cervical LN LD 51 F - - + - ND ++++ high 
15 4014/13 cervical LN MC 65 M - + +   ND - low 
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16 4784/13 cervical LN Nodular LP 17 M + - + + EMA + - low 
17 755/14 cervical LN NS 33 F - + + - ND + low 
18 807/14 inguinal LN LD 77 M - - + - ND + low 
19 1045/14 cervical LN NS 16 F - + + - ND +++ high 
20 1499/14 cervical LN MC 46 M - + + - ND +++ high 
21 1634/14 cervical LN NS 15 M - + + - ALK - - low 
22 2448/14 Inguinal LN MC 41 M - - + - ND + low 
23 2561/14 supraclavicular 
LN 
NS 23 M - + + - ND - low 
24 3957/14 supraclavicular 
LN 
MC 13 M - + + - ND - low 
25 4101/14 cervical LN MC 7 M - - + - ND + high 
26 4197/14 Omentum MC 63 M - + + - ND ++ high 
27 4588/14 Axillary LN MC 77 M - + + - ND ++ low 
28 376/15 cervical LN NS 19 F - + - - ND - high 
29 1378/15 cervical LN NS 24 M - + + - ND - high 
30 2182/15 cervical LN NS 33 M - - + - ALK- - high 
EMA-  
31 2701/15 cervical LN NS 55 M - + + - ND ++++ high 
32 3189/15 paratracheal LN MC 47 M - + - - ND + high 
33 3337/15 Axillary LN MC 30 M - - + - ND ++ high 
34 4552/15 paratracheal LN MC 58 M - + + - ND ++++ high 
 
